Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $50.00 | Buy | TD Cowen |
| 8/2/2023 | $16.00 → $12.00 | Sell → Neutral | Goldman |
| 6/26/2023 | $55.00 → $40.00 | Buy | Jefferies |
| 5/20/2022 | $5.00 | Underperform | BofA Securities |
| 2/23/2022 | $49.00 → $35.00 | Buy | B. Riley Securities |
| 1/28/2022 | $70.00 → $68.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $75.00 → $70.00 | Buy | HC Wainwright & Co. |
| 12/1/2021 | $55.00 → $36.00 | Outperform | Evercore ISI Group |
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An a
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00
Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously
Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously
10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: No Association Between Decreases in Serum Immunoglobulin (Ig) Levels
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting including updated data from the ENHANCE trial, which aims to ex
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity